Inactive Instrument

Rich Pharmaceuticals, Inc.

Equities

RCHA

US76303T4076

Biotechnology & Medical Research

Rich Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

June 10, 2015

Rich Pharmaceuticals, Inc. filed its S-1/A on Jun 11, 2015 for the period ending Mar 31, 2014. In this report its auditor, Silberstein Ungar, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Rich Pharmaceuticals, Inc.

Rich Pharmaceuticals, Inc. Announces Board Changes	21-07-06	CI
Rich Pharmaceuticals, Inc. Announces Executive Changes	21-07-06	CI
Geopulse Exploration, Inc. cancelled the acquisition of unknown stake in Rich Pharmaceuticals, Inc..	20-10-06	CI
Geopulse Exploration, Inc. signed an agreement to acquire unknown stake in Rich Pharmaceuticals, Inc..	19-10-06	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.0515 million in funding from GHS Investments, LLC	18-03-14	CI
Rich Pharmaceuticals, Inc Announces Study Drug RP-323 Is A Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma	18-03-14	CI
Rich Pharmaceuticals, Inc. announced that it has received CNY 0.06 million in funding from GHS Investments, LLC	18-01-09	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.03 million in funding from GHS Investments, LLC	17-11-02	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	17-10-15	CI
Rich Pharmaceuticals, Inc. Enters into Support and Collaboration Agreement with Mega Bridge, Inc	17-07-12	CI
Rich Pharmaceuticals, Inc. will Change its Ticker to RCHA.D from RCHA	17-06-07	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.025 million in funding from GHS Investments, LLC	17-04-17	CI
Rich Pharmaceuticals, Inc. Appoints Carole A. Salvador as Director	17-04-10	CI
Rich Pharmaceuticals, Inc.'s New Division Canncodex Appoints Justin Braune as Member of the Canncodex Advisory Board	17-04-06	CI
Rich Pharmaceuticals, Inc. Reaches Agreement with I Tech Health Corp. to Form a Subsidiary and Launch CannCodex	17-03-21	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from GHS Investments, LLC	17-01-04	CI
Rich Pharmaceuticals, Inc. announced that it expects to receive $0.03 million in funding from LG Capital Funding, LLC	16-10-19	CI
Rich Pharmaceuticals, Inc. announced that it has received $0.112 million in funding from LG Capital Funding, LLC	16-06-24	CI
Rich Pharmaceuticals Agrees Additional Contract with Theradex Systems	16-06-23	CI
Rich Pharmaceuticals, Inc. announced that it will receive $0.11 million in funding from LG Capital Funding, LLC	16-06-22	CI
Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS	15-12-28	CI
Rich Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	15-09-16	CI
Rich Pharmaceuticals, Inc. Announces Board Changes	15-08-10	CI
Rich Pharmaceuticals, Inc. will Change its Ticker to RCHAE from RCHA	15-07-17	CI
Rich Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	15-06-10	CI

Chart Rich Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rich Pharmaceuticals, Inc. is a development-stage company. The Company is a biopharmaceutical company focused on developing and commercializing therapies in oncology. The Company is developing 12-O-tetradecanoylphorbol-13-acetate (RP-323) for the treatment of Hodgkin's lymphoma (HL), Acute Myelogenous Leukemia (AML) and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. RP-323 is a naturally occurring compound. RP-323 converts cancer cells to normal cells, a process called differentiation. It is also observed in some instances to cause cancer cell death. Clinical studies in over 100 cancer patients demonstrated the ability of RP-323 to stimulate the production of white blood cells and neutrophils. The Company has no products ready for commercialization. The Company had no revenues during the period ending March 31, 2016.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs